Clinical Trial: A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint

U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07140744) titled 'A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint' on Aug. 22.

Brief Summary: The purpose of the study is to measure the difference in the proportion of participants with prespecified patient management actions between a tested interventional group and a control group.

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Subjective Cognitive Impairment

Intervention: DIAGNOSTIC_TEST: P-tau217

Blood biomarker testing

OTHER: Standard of Care

Standard of care

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Eli Lill...